Caxton Associates LP Bristol Myers Squibb CO Transaction History

Caxton Associates LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $68,611 - $77,792	1,430 Added 5.51%	27,369 $1.48 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $822,269 - $919,424	14,204 Added 121.04%	25,939 $1.51 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $112,830 - $125,280	1,771 Added 17.77%	11,735 $750,000
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $1.05 Million - $1.19 Million	-15,940 Reduced 61.53%	9,964 $690,000
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $1.77 Million - $2.1 Million	25,904 New	25,904 $1.86 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $586,914 - $646,398	8,082 New	8,082 $622,000
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $632,821 - $701,249	-11,019 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $604,061 - $706,207	11,019 New	11,019 $648,000
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $231,023 - $287,944	-4,572 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $273,954 - $315,376	4,572 New	4,572 $289,000
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $364,518 - $420,684	-6,600 Closed	0 $0
Q2 2017 Aug 29, 2017	BUY	N/A	6,600	6,600 $368,000

2,425

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.